A Prospective, Real-World Study Evaluating the Impact of RISankizumab on BurdEn of Disease in Ulcerative Colitis in JaPan (RISE UP)

A Prospective, Real-World Study Evaluating the Impact of RISankizumab on BurdEn of Disease in Ulcerative Colitis in JaPan (RISE UP) - RISE UP study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059341

Enrollment

200

Registered

2025-10-08

Start date

2025-09-30

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: No formal Exclusion criteria exist

Design outcomes

Primary

Measure	Time frame
Achievement of clinical remission per Partial Adapted Mayo Score at Week 52	—

Secondary

Measure	Time frame
-Achievement of no BU, AP, NBM, FI, SI, tenesmus. -Achievement of clinical response and clinical remission per Partial Adapted Mayo Score. -Achievement of endoscopic improvement and remission. -Achievement of clinical remission per Adapted Mayo Score.	—

Countries

Japan

Contacts

Public ContactAbbVie GK Clinical Trial Registration Desk -

AbbVie GK Medical Affairs

abbvie_jpn_info_clingov@abbvie.com03-4577-1111

Outcome results